Products / Trail Range Livestock / Colostrum Complete

RangeStart · Bovine

Colostrum Complete

A colostrum supplement concept, distinct from the replacer beside it. A supplement adds to maternal colostrum; a replacer stands in for it entirely. The distinction is not a marketing tier — a supplement's immunoglobulin figure is only meaningful alongside an assumption about the maternal colostrum it supplements, which the producer controls and we do not.

Livestock healthBovine

The panel itself

Read the label, not a description of it

The artwork that goes on the pack, beside the guarantee it carries.

Colostrum Complete

Label panel pending

Why this band exists

A buyer comparing two bags is reading label panels. Showing ours at full size, beside the same figures in the table above, is a claim that cannot be made cheaply: it requires the artwork and the specification to already agree.

Where the artwork does not exist yet the band still builds, with a marked placeholder holding the space — so the page keeps one shape across the range and a missing panel reads as pending rather than as a design that broke.

Market role

Nutrition & Performance for Livestock Production

Trail Range Livestock provides the broader livestock architecture. FirstLight is the endorsed neonatal brand within the RangeStart early-life line, focused on colostrum development.

FarmsRanchesLivestock professionalsAgricultural distributors

Line-level context, shown here because it answers “what is this for” at the moment someone is looking at one product. The line page carries it in full.

Formulation direction

What the evidence supports — and what it does not.

Development inputs, not finished formulas. Each candidate is graded on the published evidence, including the ingredients the evidence tells us to leave out.

Colostrum programs and neonatal nutrition

Establishing passive immunity in the first 24 hours, when gut closure limits the absorption window.

Lead with

IgG source and absorption efficiency, not IgG mass alone
Established
The decisive formulation insight in this category. Apparent efficiency of absorption measured 38.8% for a colostrum-derived product against 21.6% for a plasma-derived one, producing very different passive-transfer rates from comparable IgG mass. Source selection outranks dose.
Basis2013Controlled study 2007Controlled study
Clinoptilolite in the first-24-hour colostrum window, at low inclusion
Emerging
One controlled trial (n=60) found higher serum IgG and higher apparent efficiency of absorption when a clinoptilolite suspension accompanied colostrum; a second (n=18) found γ-globulin — a proxy measure, not IgG directly — above control at 0.5%. Both point to enhancement rather than interference, and both come from closely related research groups, with the window set by gut closure. Critically dose-dependent: roughly 0.5% of the meal outperformed 2%, and higher intakes turn the effect the other way. Tolerance at up to 2% of milk replacer over 28 days is separately documented. Specify clinoptilolite by name and CAS number: chabazite, phillipsite and synthetic zeolite A are different materials with different behaviour and no transferable evidence.
Basis2008Controlled study 2018Controlled study 2008Controlled study
Oral electrolyte formulation for rehydration
Moderate
Oral electrolyte solution outperformed intravenous and subcutaneous routes for restoring plasma volume and correcting blood pH in calves retaining gut function. Sodium content, alkalinising capacity, energy source and osmolality are the formulation variables.
Basis2019Controlled study

Deprioritise or exclude

Inherited category performance data
Counter-indicated
Performance is product-specific. One marketed replacer achieved adequate passive transfer in 6.9% of calves against 72% on maternal colostrum. No product may borrow another's result, and the disease-risk epidemiology attached to failure of passive transfer is associational, not a measured product effect.
Basis2016Systematic review 2007Controlled study

Claim ceiling. Composition only until licensed. Marketing a product as treating failure of passive transfer requires a USDA veterinary biologic licence; immune and immunoglobulin claims fall under biologics licensing, not feed registration. A numeric designation may denote verified IgG per dose but must never imply achieved serum IgG.

Substantiation required. Product-specific passive-transfer verification against an untreated arm, analytical IgG method and lot consistency, and — for any replacer or immunity positioning — the licensing pathway rather than feed registration.

Every brief covering RangeStart is shown rather than only those bearing on this product, because a brief is a development input for a category and not a statement about one item. Narrowing it further needs a per-product category on the record.

Evidence map

The sources this product answers to — with their limits visible.

These sources guide standards, ingredient review and study design. They do not automatically substantiate an unfinished product.

11 sources · 2026 back to 2007

2026 · Regulatory guidance

9 CFR Part 102 — licensing of veterinary biological products

USDA APHIS (Virus-Serum-Toxin Act, via eCFR)

Scope. Establishment and product licence requirements, and the data establishing purity, safety, potency and efficacy that an application must include.

Supports. Defines the pathway for any product presented as acting on immunity, and requires that all claims intended for labels and advertising be submitted as part of the application.

Does not establish. Does not apply to products marketed purely on nutrient contribution; conversely, no feed registration substitutes for a biologic licence where an immunity claim is made.

Primary source ↗

2020 · Consensus recommendations

Consensus recommendations on calf- and herd-level passive immunity in dairy calves in the United States

Journal of Dairy Science

Scope. Replaces the binary pass/fail passive-transfer standard with four serum IgG categories and corresponding herd-level distribution goals.

Supports. The current US reference framework against which a colostrum program and any product used within it should be benchmarked and monitored.

Does not establish. Does not establish that any product or protocol moves calves between categories; it defines measurement thresholds and herd targets, not interventions.

Primary source ↗

2019 · Controlled study

Comparison of oral, intravenous and subcutaneous fluid therapy for resuscitation of calves with diarrhea

Journal of Dairy Science

Scope. Randomised trial in calves with induced diarrhoea and dehydration comparing oral electrolyte solution against intravenous and subcutaneous routes.

Supports. Substantiates a properly formulated oral electrolyte as first-line rehydration for calves that retain a functional gut.

Does not establish. Does not reflect naturally occurring disease — diarrhoea was experimentally induced, acidemia was relatively mild, and treatment arms were not composition-matched.

Primary source ↗

2018 · Controlled study

Serum protein electrophoretic pattern in neonatal calves treated with clinoptilolite

Molecules

Scope. 18 calves in three groups — colostrum alone, colostrum plus 0.5% clinoptilolite, colostrum plus 2% — dosed within two hours of birth and again at 12 and 24 hours.

Supports. The only head-to-head dose comparison in the colostrum window: at 30 hours the 0.5% group showed γ-globulin markedly above control, and the authors conclude the lower dose was the more effective of the two.

Does not establish. Does not measure IgG directly (γ-globulin is a proxy), uses six calves per arm, records no clinical endpoint, and shows the higher 2% dose performing worse than 0.5% — the effect is dose-critical, not linear.

Primary source ↗

2016 · Systematic review

Failure of passive immune transfer in calves: a meta-analysis on the consequences and assessment of the economic impact

PLOS ONE

Scope. Meta-analysis of 68 published models quantifying adjusted risk of mortality, respiratory disease, diarrhoea and overall morbidity associated with failure of passive transfer.

Supports. Quantifies the health burden attached to failure of passive transfer, justifying it as a high-value development target.

Does not establish. Does not demonstrate that raising serum IgG by any given intervention delivers a proportional reduction in disease — the estimates are associational, with substantial heterogeneity.

Primary source ↗

2016 · Systematic review

Diagnostic accuracy of refractometry for assessing bovine colostrum quality: a systematic review and meta-analysis

Journal of Dairy Science

Scope. Meta-analysis of 11 studies and 4,251 colostrum samples evaluating Brix refractometry against an IgG standard at different cutoffs.

Supports. Validates on-farm Brix as a screening input for colostrum quality decisions and quantifies the confidence each cutoff carries.

Does not establish. Does not establish that Brix predicts a calf's achieved serum IgG — it measures agreement with colostral IgG concentration only.

Primary source ↗

2016 · Systematic review

Invited review: transitioning from milk to solid feed in dairy heifers

Journal of Dairy Science

Scope. Review of rumen ecosystem development, fermentation, papillae growth and rumination behaviour across the milk-to-solid-feed transition.

Supports. Informs starter formulation direction — specifically the balance between physically effective fibre and readily degradable carbohydrate.

Does not establish. Does not provide a validated numeric formulation specification, and as a narrative review applies no systematic risk-of-bias appraisal.

Primary source ↗

2013 · Controlled study

Effect of feeding maternal colostrum or plasma-derived or colostrum-derived colostrum replacer on passive transfer, health and performance of preweaning heifer calves

Journal of Dairy Science

Scope. Three-arm trial comparing maternal colostrum against plasma-derived and colostrum-derived replacers, measuring apparent efficiency of absorption and passive-transfer adequacy.

Supports. Establishes that IgG source and absorption efficiency — not IgG mass alone — drive achieved serum IgG, a core formulation consideration.

Does not establish. Does not establish an upper bound on replacer performance, as it tested a single dose of each replacer rather than dose-matched IgG.

Primary source ↗

2008 · Controlled study

Apparent efficiency of immunoglobulin absorption in newborn calves orally treated with zeolite

Acta Veterinaria

Scope. 60 Holstein calves in four groups, fed colostrum at two volumes with or without a 25% clinoptilolite suspension, measuring serum IgG and apparent efficiency of absorption.

Supports. The largest trial addressing clinoptilolite and colostral immunoglobulin directly: serum IgG at six hours was significantly higher with zeolite at the lower colostrum volume, and apparent efficiency of absorption was highest in that group — the mineral enhanced rather than impaired absorption.

Does not establish. Does not establish a mechanism, was not blinded, records no clinical outcomes such as morbidity or scours, and comes from a single research group.

Primary source ↗

2008 · Controlled study

Clinical observations, biochemical data and postmortem findings in young dairy calves fed zeolite clinoptilolite with milk replacer

American Journal of Veterinary Research

Scope. 26 Holstein calves fed milk replacer with 0%, 0.5% or 2% clinoptilolite twice daily for 28 days, all necropsied.

Supports. The best tolerance dataset in neonatal calves — no gross lesions attributable to treatment at necropsy, and no adverse haematology or biochemistry.

Does not establish. Does not show any benefit; it was designed as a safety study, found no difference in bodyweight or average daily gain, and reported an unexplained increase in jejunal mucosal eosinophils in treated calves.

Primary source ↗

2007 · Controlled study

Passive transfer of immunoglobulin G and preweaning health in Holstein calves fed a commercial colostrum replacer

Journal of Dairy Science

Scope. Trial comparing maternal colostrum against a commercial colostrum replacer regimen, measuring 24-hour serum IgG and passive-transfer adequacy.

Supports. Demonstrates directly that a marketed colostrum replacer can fail to deliver adequate passive transfer, establishing why product-specific validation is mandatory.

Does not establish. Does not generalise to all replacers — the result characterises one product and dosing regimen, not the category.

Primary source ↗

Rest of the line

RangeStart

FirstLight IgG 24

Pack render pending

FirstLight IgG 24

Livestock health · Bovine

Electrolyte Advanced

Pack render pending

Electrolyte Advanced

Livestock health · Bovine

Calf Start Advantage

Pack render pending

Calf Start Advantage

Livestock health · Bovine

Documentation

What a buyer can ask for

Three documents, and the state each is actually in. A buyer asking “what can you send me?” wants the answer as a list of things they can request, not as a status band they have to interpret.

Composition only

Specification packet

Formulation, guarantees, the acceptance windows each is judged against and the regulatory edition in force, with a revision hash so two copies can be told apart. Mass per dose, minimum concentration and the assay that verifies it are settled; the ingredient statement waits on a source declaration, and no performance section exists.

Available now

Claim sheet

Every claim the label makes, the basis for each one, and — the part buyers rarely get — the terms we have deliberately not used, with the reason.

On manufacture

Certificate of analysis

Per lot, assayed against the acceptance windows above. Available once a production run exists — which is also when the guaranteed analysis stops being a target and becomes a result.

Documentation statusSpecified on composition

Specified on composition and proceeding without the absorption trial. Every figure a buyer can hold us to — mass per dose, minimum concentration, the assay that proves it — is settled and verifiable per lot. The trial gates performance claims only, and those are excluded from the label either way.

Documented

Dose specified: a 104 g scoop delivering 25 g IgG at the 24% minimum, twelve scoops to a 2.75 lb (1.25 kg) pack. Fed at one to three scoops, because a supplement is titrated against the maternal colostrum the calf already received.
Specification proceeds without the absorption trial. Composition is measured in a laboratory; absorption is measured in a calf. Only the second needed the trial, and the first is what a buyer purchases and what a lot is released against.
The floor is evidence, not preference: a replacer fed at 125 g IgG produced 93.1% failure of passive transfer, and the review range is 150–200 g — twenty percent of dose separates those outcomes, so 150 g is a floor rather than a midpoint.
Pack architecture follows from the dose — one unit is one dose for one calf, so no partial dose can be fed short or discarded at the single feeding where accuracy decides the outcome.
Immunoglobulin concentration specified as a manufacturing minimum, verified per lot by radial immunodiffusion. Lots below the minimum are rejected or reblended.
Front-panel layout, identity statement and directions structure written.
Claim ceiling settled: composition may be stated as verified fact; achieved passive transfer may not be promised.
Internal SKU assigned, one per saleable pack.

Not yet established

No statement about achieved passive transfer, serum immunoglobulin or absorption efficiency is available, and none will be made without a trial. A dose is defensible on the published floor; what a calf does with it is measured, not reasoned — one marketed replacer achieved adequate passive transfer in 6.9% of calves against 72% on maternal colostrum.
The absorption trial is now elective rather than blocking: single arm, n = 30, paired 0 h and 24 h radial immunodiffusion, design and costing complete. Running it buys performance language and nothing else. Not running it costs no compositional figure on this page.
Colostrum source not yet declared — a sourcing decision, not a trial result. Colostrum-derived and plasma-derived immunoglobulin behave differently at comparable mass, and the ingredient statement and proximate analysis both follow from that choice. This is the one thing still holding the packet short of complete.
Processing parameters not yet locked. Irradiation dose linearly reduced both 24-hour serum IgG and apparent efficiency of absorption in the same product, so sterilisation and drying belong in the manufacturing specification whether or not a trial ever runs — and if one does, it is invalid unless they were locked first.
No production batch has been made. A guaranteed analysis is derived from assay of finished batches — mean − 2 SD for minima, mean + 2 SD for maxima — so every figure shown is the value the formula is built to, not a verified result.
Retail GTIN-12 pending. A UPC must be licensed from GS1 under the registered brand owner; internal SKUs are not substitutes and are not scannable.
Supplied packaging artwork is concept art. Names, claims, formats and sizes shown on an image are not approved product facts.

Claim ceiling: Composition may be stated as verified fact; achieved passive transfer may not be promised. This is a supplement fed alongside maternal colostrum, never a replacement for it, and the identity statement carries more weight than the immunoglobulin figure. Presenting a product as acting on the immune system makes it a USDA veterinary biologic rather than a feed, and independently creates an unapproved new animal drug — the two exposures stack.